Evaluation of Rovadicitinib Compared to the Protocol Selected by Researchers in Third Line and Subsequent Studies of Moderate to Severe Chronic Graft-versus-host Disease
研究单位：[1]Chia Tai Tianqing Pharmaceutical Group Co., Ltd.[2]The First Affiliated Hospital of USTC Anhui Provincial Hospital,Hefei,Anhui,China,230001[3]Peking University First Hospital,Beijing,Beijing,China,100034[4]Peking University People's Hospital,Beijing,Beijing,China,100044[5]The Southwest Hospital of AMU,Chongqing,Chongqing,China,400038[6]Fujian Medical University Union Hospital,Fuzhou,Fujian,China,350001[7]The First Affiliated Hospital of Xiamen University,Xiamen,Fujian,China,361003[8]The First Hospital of Lanzhou University,Lanzhou,Gansu,China,730000[9]The 904 Hospital of the Joint Service Support Force of the People's Liberation Army of China,Lanzhou,Gansu,China,730050[10]Guangzhou First People's Hospital The First People's Hospital Affiliated to Guangzhou Medical University,Guangzhou,Guangdong,China,510180[11]Nanfang Hospital,Guangzhou,Guangdong,China,510515[12]The First Affiliated Hospital of Guangxi Medical University,Nanning,Guangxi,China,530021[13]The Affiliated Hospital of Guizhou Medical University,Guiyang,Guizhou,China,550001[14]The Second Hospital of Hebei Medical Hospital,Shijiazhuang,Hebei,China,050000[15]Henan Provincial People's Hospital,Zhengzhou,Henan,China,450003[16]The Third People's Hospital of Zhengzhou,Zhengzhou,Henan,China,450099[17]Henan Cancer Hospital,Zhenzhou,Henan,China,450000[18]Wuhan Union Hospital of China,Wuhan,Hubei,China,430022[19]Tongji Hospital Tongji Medical College of HUST,Wuhan,Hubei,China,430030[20]Zhongnan Hospital of Wuhan University,Wuhan,Hubei,China,430071[21]The Second Xiangya Hospital of Central South University,Changsha,Hunan,China,Hunan[22]Huai'an Second People's Hospital,Huai'an,Jiangsu,China,223200[23]Zhongda Hospital Southeast University,Nanjing,Jiangsu,China,210009[24]Jiangsu Province Hospital,Nanjing,Jiangsu,China,210029[25]The First Affiliated Hospital of Nanchang University,Nanchang,Jiangxi,China,330006[26]First Hospital of Jilin University,Changchun,Jilin,China,130031[27]The First Hospital of China Medical University,Shenyang,Liaoning,China,110001[28]Qilu Hospital of Shandong University,Jinan,Shandong,China,250012[29]Tai'an City Central Hospital,Tai'an,Shandong,China,271000[30]Shanghai Jiao Tong University School of Medicine，Renji Hospital,Shanghai,Shanghai,China,200001[31]Ruijin Hospital, Shanghai Jiaotong University School Of Medicine,Shanghai,Shanghai,China,200025[32]Shanxi Bethune Hospital,Taiyuan,Shanxi,China,030032[33]The First Affiliated Hospital of Xi'an Jiaotong University,Xi'an,Shanxi,China,710061[34]Shanxi Provincial People's Hospital,Xi'an,Shanxi,China,710068[35]Sichuan Provincial People's Hospital,Chengdu,Sichuan,China,610072[36]Chinese Academy of Medical Sciences Hematology Hospital,Tianjin,Tianjin,China,300052[37]The First Hospital of Xinjiang Medical University,Ürümqi,Xinjiang,China,830054[38]The First People's Hospital of Yunnan Province,Kunming,Yunnan,China,650032[39]The First Affiliated Hospital, Zhejiang University School of Medicine,Hangzhou,Zhejiang,China,310003[40]The Affiliated People's Hospital of Ningbo University,Ningbo,Zhejiang,China,315040[41]The First Affiliated Hospital of Ningbo University,Ningbo,Zhejiang,China,315211[42]The First Affiliated Hospital of Wenzhou Medical University,Wenzhou,Zhejiang,China,325005
研究目的：
The aim of this study is to demonstrate that in subjects with moderate to severe chronic graft-versus-host disease in the third line and beyond, the use of rosuvastatin compared to the protocol chosen by the researchers can significantly improve the objective response rate of subjects at week 24.
